연구
교육
솔루션
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Mitochondrial Medicine Frontier Program,
Division of Human Genetics,
Department of Pediatrics,
Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics
Eiko Nakamaru-Ogiso has not added Biography.
If you are Eiko Nakamaru-Ogiso and would like to personalize this page please email our Author Liaison for assistance.
Bacteria, yeast, worms, and flies: exploiting simple model organisms to investigate human mitochondrial diseases.
Developmental disabilities research reviews Jun, 2010 | Pubmed ID: 20818735
Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
EMBO molecular medicine Jul, 2011 | Pubmed ID: 21567994
NMNAT1 mutations cause Leber congenital amaurosis.
Nature genetics Sep, 2012 | Pubmed ID: 22842227
Primary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling network.
PloS one , 2013 | Pubmed ID: 23894440
Mitochondrial DNA variant in COX1 subunit significantly alters energy metabolism of geographically divergent wild isolates in Caenorhabditis elegans.
Journal of molecular biology May, 2014 | Pubmed ID: 24534730
Pharmacologic targeting of sirtuin and PPAR signaling improves longevity and mitochondrial physiology in respiratory chain complex I mutant Caenorhabditis elegans.
Mitochondrion May, 2015 | Pubmed ID: 25744875
Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish.
Neurochemistry international 07, 2018 | Pubmed ID: 28732770
Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease.
Human molecular genetics 06, 2019 | Pubmed ID: 30668749
Regulation of nuclear epigenome by mitochondrial DNA heteroplasmy.
Proceedings of the National Academy of Sciences of the United States of America 08, 2019 | Pubmed ID: 31253706
Combinatorial glucose, nicotinic acid, and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease.
Human molecular genetics Feb, 2021 | Pubmed ID: 33640978
The Children’s Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Manuela Lavorato*,1,
Neal D. Mathew*,1,
Nina Shah1,
Eiko Nakamaru-Ogiso1,2,
Marni J. Falk1,2
1Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, The Children’s Hospital of Philadelphia,
2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유